Brief: Sino Biopharmaceutical Enters Exclusive License Agreement With Astrazeneca For TQC3721
07/07/2026 23:08
BRIEF-Sino Biopharmaceutical Enters Exclusive License Agreement With Astrazeneca For TQC3721 July 8 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:
ENTERS EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA FOR TQC3721
ASTRAZENECA GRANTED EXCLUSIVE RIGHTS TO TQC3721 OUTSIDE CHINA
ELIGIBLE FOR $200 MILLION UPFRONT, MILESTONES UP TO $1.9 BILLION, AND TIERED ROYALTIES
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains